Angela Frances Holtham Acquires 7,000 Shares of Oncolytics Biotech Inc. (TSE:ONC) Stock

Oncolytics Biotech Inc. (TSE:ONC) Director Angela Frances Holtham purchased 7,000 shares of the firm’s stock in a transaction dated Monday, June 7th. The shares were bought at an average price of C$3.59 per share, with a total value of C$25,123.70. Following the purchase, the director now owns 108,336 shares in the company, valued at approximately C$388,828.74.

TSE ONC opened at C$3.60 on Friday. Oncolytics Biotech Inc. has a twelve month low of C$2.00 and a twelve month high of C$6.06. The company has a quick ratio of 20.96, a current ratio of 22.15 and a debt-to-equity ratio of 1.40. The firm has a market cap of C$196.80 million and a PE ratio of -5.37. The business’s 50-day simple moving average is C$3.83.

Oncolytics Biotech (TSE:ONC) last posted its quarterly earnings data on Friday, May 7th. The company reported C($0.13) earnings per share for the quarter, topping the consensus estimate of C($0.21) by C$0.08. As a group, sell-side analysts predict that Oncolytics Biotech Inc. will post -0.39 earnings per share for the current fiscal year.

ONC has been the subject of several recent analyst reports. Royal Bank of Canada reiterated an “outperform” rating and set a C$6.00 price target on shares of Oncolytics Biotech in a research note on Friday, May 21st. Leede Jones Gab reiterated a “speculative buy” rating on shares of Oncolytics Biotech in a research note on Wednesday, February 24th. Finally, HC Wainwright reissued a “buy” rating on shares of Oncolytics Biotech in a research report on Wednesday, February 17th.

About Oncolytics Biotech

Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC.

Featured Story: Trade Deficit

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with's FREE daily email newsletter.